KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) Other Operating Expenses (2020 - 2026)

Pacific Biosciences Of California has reported Other Operating Expenses over the past 7 years, most recently at -$1.9 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses fell 102.1% year-over-year to -$1.9 million; the TTM value through Dec 2025 reached $347.8 million, up 85.14%, while the annual FY2025 figure was $347.8 million, 85.14% up from the prior year.
  • Other Operating Expenses for Q4 2025 was -$1.9 million at Pacific Biosciences Of California, down from -$1.6 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $353.2 million in Q1 2025 and troughed at -$52.0 million in Q1 2021.
  • A 5-year average of $28.6 million and a median of $626000.0 in 2024 define the central range for Other Operating Expenses.
  • On a YoY basis, Other Operating Expenses climbed as much as 15984.29% in 2025 and fell as far as 360.06% in 2025.
  • Year by year, Other Operating Expenses stood at -$52.0 million in 2021, then surged by 103.95% to $2.1 million in 2022, then skyrocketed by 70.46% to $3.5 million in 2023, then skyrocketed by 2501.68% to $91.1 million in 2024, then tumbled by 102.1% to -$1.9 million in 2025.
  • Business Quant data shows Other Operating Expenses for PACB at -$1.9 million in Q4 2025, -$1.6 million in Q3 2025, and -$1.8 million in Q2 2025.